Iminostilbene voltage-gated sodium channel blocker

Plain-language summaryIntrigue 60 / 100

Carbamazepine (Tegretol) is a first-generation anticonvulsant from Geigy, synthesized in 1953 and FDA-approved in 1968. It blocks voltage-gated sodium channels much like lamotrigine and is broadly effective for partial seizures, trigeminal neuralgia (where it is first-line), and bipolar mania. Its big practical headache is potent induction of the liver enzyme CYP3A4, which means it accelerates the breakdown of many other drugs (oral contraceptives, warfarin, many antidepressants), creating constant interaction problems. It also induces its own metabolism, so doses often need to climb in the first few weeks. The active leftover is a structurally similar epoxide that contributes to both the therapeutic effect and the side effects. Aplastic anemia and Stevens-Johnson syndrome are rare but serious risks. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

39/100

First-generation sodium channel blocker, proven and approved, long superseded as a novel research target

Look, carbamazepine is a 70-year-old drug that works. The mechanism, state-dependent voltage-gated sodium channel inhibition, was characterized decades ago and hasn’t gotten more interesting since. What carbamazepine does best is be reliable, and that reliability is precisely what limits its appeal as a live research target in 2024.

The evidence base is genuinely impressive, in the way that things that have been FDA-approved since 1968 tend to be. Hundreds of replicated trials for partial-onset seizures, tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania. The translational arrow points straight down from bench to clinic because that work was done half a century ago. We’re not learning new things about carbamazepine; we’re using what we already know.

The differentiation story is the hard part. Oxcarbazepine was developed specifically to strip out carbamazepine’s worst liabilities, the potent CYP3A4 induction that wrecks contraceptive coverage and immunosuppressant dosing, the aplastic anemia and agranulocytosis risk, the SJS/TEN exposure in HLA-B*1502 carriers. Lacosamide took the sodium channel story in a more selective direction with slow-inactivation preference. Lamotrigine achieved a cleaner dual-mechanism profile with a better tolerability envelope. Carbamazepine retains the reference iminostilbene label, and thats genuinely useful for comparative class pharmacology. But if youre designing a new research program on voltage-gated sodium channels, you probably dont open with this one.

Honestly, where it still earns real bench credit is narrow but real. The auto-induction kinetics are a legitimate research model: the half-life collapses from 25-65 hours at first dose to 12-17 hours at steady state as it induces its own CYP3A4-mediated clearance, which makes it one of the cleaner in vivo models for studying auto-induction biology. The HLA-B*1502 pharmacogenomics work around SJS/TEN prediction in East and Southeast Asian populations is live research, and carbamazepine is the reference exposure for those studies. Those are real questions. They’re just not the kind of questions that drive high-priority bench allocations.

We think this belongs in the library as a reference standard and a pharmacogenomics model, not as a compound with active research momentum. A serious investigator looking for fresh signal in sodium channel pharmacology, CNS excitability, or mood stabilization would not prioritize carbamazepine in 2024. The science is largely settled. The score reflects that.

Novelty: 12
Mechanism promise: 20
In-category differentiation: 28
Evidence quality: 78
Translational signal: 72
Research bench value: 45

Rationale Carbamazepine scores high on evidence and translational signal because it is a fully approved drug with massive clinical literature, but novelty and mechanism promise are floor-level for a 1953 compound with a well-mapped, single-channel mechanism that newer agents have largely refined away. The reference probe angle gives it modest bench value, but this is not a compound generating new science.

Iminostilbene voltage-gated sodium channel blocker

A first-generation iminostilbene anticonvulsant and mood stabilizer with potent CYP3A4 induction.

Abstract

Carbamazepine (5H-dibenzo[b,f]azepine-5-carboxamide; CAS 298-46-4; molecular formula C15H12N2O; molecular weight 236.27) is an iminostilbene anticonvulsant developed by Walter Schindler at Geigy in 1953 and approved by the FDA in 1968 under the trade name Tegretol. Mechanism: state-dependent voltage-gated sodium channel inhibition (similar to lamotrigine), producing reduced neuronal hyperexcitability in seizure foci. Active metabolite carbamazepine-10,11-epoxide retains anticonvulsant activity. Plasma half-life is 25 to 65 hours initially but auto-induces own metabolism, dropping to 12 to 17 hours at steady state. Strong CYP3A4 induction produces clinically significant interactions with hormonal contraception, immunosuppressants, anticoagulants, antiretrovirals, and many other drugs. Approved for partial-onset and generalized tonic-clonic seizures, trigeminal neuralgia, and bipolar I mania (in combination products). The principal safety concerns are aplastic anemia and agranulocytosis (rare but serious; HLA-B*1502 association predicts SJS/TEN risk in Asian populations and is screened pretreatment). Used as the reference iminostilbene voltage-gated sodium channel blocker.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-244Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: Iminostilbene voltage-gated sodium channel blocker

Carbamazepine

Abstract

Read the full monograph